HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Nat Med 2017 Apr 13;23(4):517-525. Epub 2017 Mar 13.

Wellcome Trust Sanger Institute, Hinxton, UK.

Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic mutations in BRCA1 and/or BRCA2 (BRCA1/BRCA2) also confer selective sensitivity to PARP inhibitors. Thus, assays to detect BRCA1/BRCA2-deficient tumors have been sought. Recently, somatic substitution, insertion/deletion and rearrangement patterns, or 'mutational signatures', were associated with BRCA1/BRCA2 dysfunction. Herein we used a lasso logistic regression model to identify six distinguishing mutational signatures predictive of BRCA1/BRCA2 deficiency. A weighted model called HRDetect was developed to accurately detect BRCA1/BRCA2-deficient samples. HRDetect identifies BRCA1/BRCA2-deficient tumors with 98.7% sensitivity (area under the curve (AUC) = 0.98). Application of this model in a cohort of 560 individuals with breast cancer, of whom 22 were known to carry a germline BRCA1 or BRCA2 mutation, allowed us to identify an additional 22 tumors with somatic loss of BRCA1 or BRCA2 and 47 tumors with functional BRCA1/BRCA2 deficiency where no mutation was detected. We validated HRDetect on independent cohorts of breast, ovarian and pancreatic cancers and demonstrated its efficacy in alternative sequencing strategies. Integrating all of the classes of mutational signatures thus reveals a larger proportion of individuals with breast cancer harboring BRCA1/BRCA2 deficiency (up to 22%) than hitherto appreciated (∼1-5%) who could have selective therapeutic sensitivity to PARP inhibition.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833945PMC
April 2017
146 Reads

Publication Analysis

Top Keywords

brca1 brca2
16
mutational signatures
12
brca1/brca2 deficiency
12
parp inhibitors
8
individuals breast
8
mutations brca1
8
brca1/brca2-deficient tumors
8
detect brca1/brca2-deficient
8
breast cancer
8
sensitivity parp
8
brca2
5
brca1/brca2
5
brca1
5
called hrdetect
4
hrdetect
4
hrdetect developed
4
model called
4
accurately detect
4
hrdetect identifies
4
identifies brca1/brca2-deficient
4

References

(Supplied by CrossRef)

EM John et al.
J. Am. Med. Assoc. 2007

KE Malone et al.
Cancer Res. 2006

FJ Couch et al.
Science 2014

MC King et al.
Science 2014

CJ Lord et al.
Nature 2012

AR Venkitaraman et al.
Science 2014

H Farmer et al.
Nature 2005

R Prakash et al.
Cold Spring Harb. Perspect. Biol. 2015

HE Bryant et al.
Nature 2005

PC Fong et al.
N. Engl. J. Med. 2009

Similar Publications